SG
At a glance
Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
3
4 agencies contacted
Activity
filings by quarter
Works on
Specific issues
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships will North American and other allied countries; Draft Senate Finance Committee drug shortage legislation, provisions relating to Medicare reimbursement policies for generic drugs; Federal policy relating to the implementation of a pharmaceutical manufacturer reliability rating system and incentives in the Medicare program for providers to purchase generic drugs from manufacturers with higher reliability ratings;
S. 4683, the National Defense Authorization Act for Fiscal Year 2025, Section 887, Requirement to produce domestically produced generic drugs, provisions relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; Federal policy relating to providing tax incentives to spur domestic manufacturing of generic drugs; and Federal policy related to Administration for Strategic Preparedness and Response initiatives to strengthen domestic pharmaceutical manufacturing capabilities.
S. 2510, the RAPID Reserve Act, provisions relating to awarding contracts to US or OECD based generic drug manufacturers to establish a reserve of essential medicines; Federal policy relating to addressing drug shortages and strengthening domestic pharmaceutical manufacturing capabilities; Federal policy relating to requiring the military to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically; Draft Senate Finance Committee drug shortage legislation, provisions relating to Medicare reimbursement policies for generic drugs; and Federal policy relating to rebating impacts on access to biosimilars
S. 2510, the RAPID Reserve Act, provisions relating to awarding contracts to US or OECD based generic drug manufacturers to establish a reserve of essential medicines; and Federal policy relating to addressing drug shortages and strengthening domestic pharmaceutical manufacturing capabilities.